Synergism between remdesivir and ribavirin leads to SARS-CoV-2 extinction in cell culture
© 2024 British Pharmacological Society..
BACKGROUND AND PURPOSE: There is a need for effective anti-COVID-19 treatments, mainly for individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug repositioning has proved effective in identifying drugs that can find a new application for the control of coronavirus disease, in particular COVID-19. The purpose of the present study was to find synergistic antiviral combinations for COVID-19 based on lethal mutagenesis.
EXPERIMENTAL APPROACH: The effect of combinations of remdesivir and ribavirin on the infectivity of SARS-CoV-2 in cell culture has been tested. Viral populations were monitored by ultra-deep sequencing, and the decrease of infectivity as a result of the treatment was measured.
KEY RESULTS: Remdesivir and ribavirin exerted a synergistic inhibitory activity against SARS-CoV-2, quantified both by CompuSyn (Chou-Talalay method) and Synergy Finder (ZIP-score model). In serial passage experiments, virus extinction was readily achieved with remdesivir-ribavirin combinations at concentrations well below their cytotoxic 50 value, but not with the drugs used individually. Deep sequencing of treated viral populations showed that remdesivir, ribavirin, and their combinations evoked significant increases of the number of viral mutations and haplotypes, as well as modification of diversity indices that characterize viral quasi-species.
CONCLUSION AND IMPLICATIONS: SARS-CoV-2 extinction can be achieved by synergistic combination treatments based on lethal mutagenesis. In addition, the results offer prospects of triple drug treatments for effective SARS-CoV-2 suppression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
British journal of pharmacology - (2024) vom: 14. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
García-Crespo, Carlos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 therapy |
|---|
| Anmerkungen: |
Date Revised 14.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/bph.16344 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371054567 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371054567 | ||
| 003 | DE-627 | ||
| 005 | 20240415234446.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bph.16344 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM371054567 | ||
| 035 | |a (NLM)38616133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a García-Crespo, Carlos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synergism between remdesivir and ribavirin leads to SARS-CoV-2 extinction in cell culture |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 British Pharmacological Society. | ||
| 520 | |a BACKGROUND AND PURPOSE: There is a need for effective anti-COVID-19 treatments, mainly for individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug repositioning has proved effective in identifying drugs that can find a new application for the control of coronavirus disease, in particular COVID-19. The purpose of the present study was to find synergistic antiviral combinations for COVID-19 based on lethal mutagenesis | ||
| 520 | |a EXPERIMENTAL APPROACH: The effect of combinations of remdesivir and ribavirin on the infectivity of SARS-CoV-2 in cell culture has been tested. Viral populations were monitored by ultra-deep sequencing, and the decrease of infectivity as a result of the treatment was measured | ||
| 520 | |a KEY RESULTS: Remdesivir and ribavirin exerted a synergistic inhibitory activity against SARS-CoV-2, quantified both by CompuSyn (Chou-Talalay method) and Synergy Finder (ZIP-score model). In serial passage experiments, virus extinction was readily achieved with remdesivir-ribavirin combinations at concentrations well below their cytotoxic 50 value, but not with the drugs used individually. Deep sequencing of treated viral populations showed that remdesivir, ribavirin, and their combinations evoked significant increases of the number of viral mutations and haplotypes, as well as modification of diversity indices that characterize viral quasi-species | ||
| 520 | |a CONCLUSION AND IMPLICATIONS: SARS-CoV-2 extinction can be achieved by synergistic combination treatments based on lethal mutagenesis. In addition, the results offer prospects of triple drug treatments for effective SARS-CoV-2 suppression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID‐19 therapy | |
| 650 | 4 | |a Quasi‐species | |
| 650 | 4 | |a error catastrophe | |
| 650 | 4 | |a lethal mutagenesis | |
| 650 | 4 | |a virus diversity | |
| 700 | 1 | |a de Ávila, Ana Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, María Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Durán-Pastor, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Somovilla, Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-González, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Flores, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Mínguez, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Salar-Vidal, Llanos |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban-Muñoz, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Cañar-Camacho, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer-Orta, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Zuñiga, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Sola, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Enjuanes, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Roblas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gadea, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Verdaguer, Nuria |e verfasserin |4 aut | |
| 700 | 1 | |a Domingo, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Perales, Celia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of pharmacology |d 1968 |g (2024) vom: 14. Apr. |w (DE-627)NLM000001325 |x 1476-5381 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bph.16344 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 14 |c 04 | ||